Pretzel Therapeutics Answers Key Questions from the POLG Community
Following the POLG Foundation Summit, Pretzel Therapeutics has shared updated answers to community questions about PX578, their first‑in‑class investigational therapy for […]
Latest News
A Major Step Forward for the Global POLG Community
FDA clears PX578 to enter Phase 2 clinical testing At IMP, few moments bring more hope than seeing innovative science
Homepage News, Latest News, News
New Natural History Study Sheds Light on MNGIE
A new retrospective natural history study from the MitoCAMB team at the University of Cambridge offers important insights into mitochondrial neurogastrointestinal
Homepage News, Latest News, News
Germany Takes a Major Step Toward Access to TK2d Therapy
A significant milestone has been reached for families affected by TK2d: Germany has now formally recognised Kygevvi®, the first disease‑specific
New Study Strengthens Patient‑Centred Endpoint Selection for KHENERFIN Phase 3 Trial
Khondrion has announced the publication of an important qualitative study in Orphanet Journal of Rare Diseases examining the lived experience
The Effects of Hydrogen Sulfide, VOCs and Bioaerosols on People with Mitochondrial Disease
Written by Paula Morandi, Chair of IMP Why emissions from olive‑pomace fermentation pose a serious health risk The open‑air fermentation
A note from the Chair: One Voice, 25 Nations — The Power of Our Global Umbrella
Paula Morandi, Chair of IMP When you hear the acronym IMP, what comes to mind? To many, International Mito Patients
Latest News, News
IMP Annual Meeting 2026 – Celebrating 15 years
The International Mito Patients (IMP) Annual Meeting 2026 brought together advocates, clinicians, researchers and partners from around the world to
Registration is now open for the TK2d International Webinar 2026 .
TK2d across countries: diagnosis, multidisciplinary care and therapeutic pathways Registration is now open for the international webinar “TK2d Across Countries: Diagnosis,
A word from our new member ASANOL
On 29 May, we had the opportunity to participate, for the first time as ASANOL, in the International Mito Patients meeting